{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:51:15Z","timestamp":1774288275717,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm that expresses the Philadelphia chromosome and constitutively activated Bcr-Abl tyrosine kinase in hematopoietic progenitor cells. Bcr-Abl tyrosine-kinase inhibitors (TKI) do not definitively cure all CML patients. The efficacy of TKI is reduced in CML patients in the blastic phase\u2014the most severe phase of the disease\u2014and resistance to this drug has emerged. There is limited knowledge on the underlying mechanisms of disease progression and resistance to TKI beyond <jats:italic>BCR-ABL1<\/jats:italic>, as well as on the impact of TKI treatment and disease progression on the metabolome of CML patients. The present study reports the metabolomic profiles of CML patients at different phases of the disease treated with TKI. The plasma metabolites from CML patients were analyzed using liquid chromatography, mass spectrometry, and bioinformatics. Distinct metabolic patterns were identified for CML patients at different phases of the disease and for those who were resistant to TKI. The lipid metabolism in CML patients at advanced phases and TKI-resistant patients is reprogrammed, as detected by analysis of metabolomic data. CML patients who were responsive and resistant to TKI therapy exhibited distinct enriched pathways. In addition, ceramide levels were higher and sphingomyelin levels were lower in resistant patients compared with control and CML groups. Taken together, the results here reported established metabolic profiles of CML patients who progressed to advanced phases of the disease and failed to respond to TKI therapy as well as patients in remission. In the future, an expanded study on CML metabolomics may provide new potential prognostic markers for disease progression and response to therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.840173","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T08:04:58Z","timestamp":1649837098000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Bioactive Lipids as Chronic Myeloid Leukemia\u2019s Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Felipe Campos","family":"de Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Berzoti-Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Mota","family":"Toro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira da Costa","family":"Cacemiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitor Leonardo","family":"Bassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel Dessotti","family":"Barretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Manoel Marques","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo Carvalho","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena Lobo","family":"de Figueiredo-Pontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Arterio","family":"Sorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia Helena","family":"Faciolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Gustavo","family":"Gardinassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fab\u00edola Atti\u00e9","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2002.1.111","article-title":"Chronic Myelogenous Leukemia","author":"Druker","year":"2002","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/stem.180399","article-title":"Consequences of BCR-ABL Expression Within the Hematopoietic Stem Cell in Chronic Myeloid Leukemia","volume":"18","author":"Kabarowski","year":"2000","journal-title":"Stem Cells"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural Course and Biology of CML","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0842-9","article-title":"Expert Opinion-Management of Chronic Myeloid Leukemia After Resistance to Second-Generation Tyrosine Kinase Inhibitors","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.10.007","article-title":"Molecular Mechanisms of Resistance of Leukemia to Imatinib Mesylate","author":"Tauchi","year":"2004","journal-title":"Leuk Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.04032","article-title":"Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease","volume":"79","author":"Yoshida","year":"2004","journal-title":"Int J Hematol"},{"key":"B9","article-title":"New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"90","author":"Martinelli","year":"2005","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-8722-6-54","article-title":"Biomarkers for Determining the Prognosis in Chronic Myelogenous Leukemia","volume":"6","author":"Sweet","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-Free Remission in Chronic Myeloid Leukemia: The Patient Perspective and Areas of Unmet Needs","volume":"34","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R600022-JLR200","article-title":"Thematic Review Series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Lipidomics: A Global Approach to Lipid Analysis in Biological Systems","volume":"47","author":"Watson","year":"2006","journal-title":"J Lipid Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3390\/cancers13030474","article-title":"Lipid Metabolism in Oncology: Why It Matters, How to Research, and How to Treat","volume":"13","author":"Matsushita","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"180167","DOI":"10.1038\/sdata.2018.167","article-title":"Comprehensive High-Resolution Multiple-Reaction Monitoring Mass Spectrometry for Targeted Eicosanoid Assays","volume":"5","author":"Sorgi","year":"2018","journal-title":"Sci Data"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2377","article-title":"A Cross-Platform Toolkit for Mass Spectrometry and Proteomics","volume":"30","author":"Chambers","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp291","article-title":"apLCMS\u2013Adaptive Processing of High-Resolution LC\/MS Data","volume":"25","author":"Yu","year":"2009","journal-title":"Bioinformatics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of Apoptosis by BCR-ABL in Chronic Myeloid Leukemia","volume":"83","author":"Bedi","year":"1994","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118820","article-title":"Bcr\/Abl Expression Stimulates Integrin Function in Hematopoietic Cell Lines","volume":"98","author":"Bazzoni","year":"1996","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400653","article-title":"Activation of Beta1 Integrins on CML Progenitors Reveals Cooperation Between Beta1 Integrins and CD44 in the Regulation of Adhesion and Proliferation","volume":"11","author":"Lundell","year":"1997","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the Increasing Prevalence and Plateau Prevalence of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: When and for Whom","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.95","article-title":"Sphingosine Kinase-1 is a Downstream Regulator of Imatinib-Induced Apoptosis in Chronic Myeloid Leukemia Cells","volume":"22","author":"Bonhoure","year":"2008","journal-title":"Leukemia [Internet]"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2174\/187152011797655122","article-title":"Targeting Sphingosine-1-Phosphate in Hematologic Malignancies","volume":"11","author":"Stevenson","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3376","article-title":"Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-Cell-Mediated Tumor Immunity","volume":"78","author":"B\u00fcll","year":"2018","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.38","article-title":"The Clinical Significance of ABCC3 as an Imatinib Transporter in Chronic Myeloid Leukaemia","volume":"28","author":"Giannoudis","year":"2014","journal-title":"Leuk"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510423103","article-title":"Gene Expression Changes Associated With Progression and Response in Chronic Myeloid Leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B27","article-title":"CML and Apoptosis: The Ceramide Pathway","volume":"40","author":"Maguer-Satta","year":"1998","journal-title":"Hematol Cell Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1212-5","article-title":"A Novel Mechanism of Dasatinib-Induced Apoptosis in Chronic Myeloid Leukemia; Ceramide Synthase and Ceramide Clearance Genes","volume":"90","author":"Gencer","year":"2011","journal-title":"Ann Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M610157200","article-title":"Alterations of Ceramide\/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-Induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells","volume":"282","author":"Baran","year":"2007","journal-title":"J Biol Chem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1194\/jlr.M033985","article-title":"Sphingomyelin Synthase 1 Activity is Regulated by the BCR-ABL Oncogene","volume":"54","author":"Burns","year":"2013","journal-title":"J Lipid Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41420-018-0075-0","article-title":"Targeting Sphingolipid Metabolism as an Approach for Combination Therapies in Haematological Malignancies","volume":"4","author":"Lewis","year":"2018","journal-title":"Cell Death Discov"},{"key":"B32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1388-1981(02)00341-4","article-title":"Sphingosine Kinase, Sphingosine-1-Phosphate, and Apoptosis","volume":"1585","author":"Maceyka","year":"2002","journal-title":"Biochim Biophys Acta"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.840173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T08:05:02Z","timestamp":1649837102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.840173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2022.840173"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.840173","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]},"article-number":"840173"}}